User menu

CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.

Bibliographic reference Elens, Laure ; Nieuweboer, Annemieke ; Clarke, Stephen J ; Charles, Kellie A ; de Graan, Anne-Joy ; et. al. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.. In: Pharmacogenomics, Vol. 14, no.2, p. 137-149 (2013)
Permanent URL
  1. Lan, Mol. Pharmacol., 58, 863 (2000)
  2. KURNIK D, WOOD A, WILKINSON G, The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity, 10.1016/j.clpt.2006.06.002
  3. WONG M, CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy*1, 10.1016/j.clpt.2004.02.005
  4. Nguyen Anh N., Hoffman Justin T., Tsunoda Shirley M., Jang In-Jin, Ma Joseph D., Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation, 10.5414/cp201701
  5. Kim Jooran S., Nafziger Anne N., Tsunoda Shirley M., Choo Edna F., Streetman Daniel S., Kashuba Angela D. M., Kulawy Robert W., Beck Debra J., Rocci Mario L., Wilkinson Grant R., Greenblatt David J., Bertino Joseph S., Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques, 10.1177/0091270002424002
  6. CHAOBAL H, KHARASCH E, Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam, 10.1016/j.clpt.2005.08.004
  7. Mathijssen R. H. J., de Jong F. A., van Schaik R. H. N., Lepper E. R., Friberg L. E., Rietveld T., de Bruijn P., Graveland W. J., Figg W. D., Verweij J., Sparreboom A., Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes, 10.1093/jnci/djh298
  8. van der Bol J. M., Mathijssen R. H.J., Creemers G.-J. M., Planting A. S.Th., Loos W. J., Wiemer E. A.C., Friberg L. E., Verweij J., Sparreboom A., de Jong F. A., A CYP3A4 Phenotype-Based Dosing Algorithm for Individualized Treatment of Irinotecan, 10.1158/1078-0432.ccr-09-1526
  9. Rivory, Clin. Cancer Res., 6, 3480 (2000)
  10. Hirth, Clin. Cancer Res., 6, 1255 (2000)
  11. Wrighton, Mol. Pharmacol., 38, 207 (1990)
  12. WANDEL C., BÖCKER R., BÖHRER H., BROWNE A., RÜGHEIMER E., MARTIN E., Midazolam is metabolized by at least three different cytochrome P450 enzymes, 10.1093/bja/73.5.658
  13. Kronbach, Mol. Pharmacol., 36, 89 (1989)
  14. Gorski J. Christopher, Jones David R., Haehner-Daniels Barbara D., Hamman Mitchell A., O'Mara Edward M., Hall Stephen D., The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin*, 10.1016/s0009-9236(98)90146-1
  15. Watkins Paul B, Hamilton Ted A, Annesley Thomas M, Ellis Charles N, Kolars Joseph C, Voorhees John J, The erythromycin breath test as a predictor of cyclosporine blood levels, 10.1038/clpt.1990.126
  16. Watkins Paul B., Noninvasive tests of CYP3A enzymes : , 10.1097/00008571-199408000-00001
  17. Turgeon D Kim, Normolle Daniel P, Leichtman Alan B, Annesley Thomas M, Smith David E, Watkins Paul B, Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients, 10.1038/clpt.1992.174
  18. Lown Kenneth S., Thummel Kenneth E., Benedict Patrick E., Shen Danny D., Turgeon Danielle K., Berent Stanley, Watkins Paul B., The erythromycin breath test predicts the clearance of midazolam*, 10.1016/0009-9236(95)90261-9
  19. Cakaloglu Yilmaz, Tredger J. Michael, Devlin John, Williams Roger, Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients, 10.1002/hep.1840200207
  20. RIVORY L, WATKINS P, Erythromycin breath test, 10.1016/s0009-9236(01)90133-x
  21. Rivory Laurent P., Slaviero Kellie A., Hoskins Janelle M., Clarke Stephen J., The Erythromycin Breath Test For the Prediction of Drug Clearance : , 10.2165/00003088-200140030-00001
  23. He P., Court M. H., Greenblatt D. J., von Moltke L. L., FACTORS INFLUENCING MIDAZOLAM HYDROXYLATION ACTIVITY IN HUMAN LIVER MICROSOMES, 10.1124/dmd.105.008904
  24. Christopher Gorski J., Hall Stephen D., Jones David R., VandenBranden Mark, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily, 10.1016/0006-2952(94)90543-6
  25. Streetman Daniel S., Bertino Joseph S., Nafziger Anne N., Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes : , 10.1097/00008571-200004000-00001
  26. Rogers J, An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity, 10.1067/mcp.2003.23
  27. Mathijssen Ron H.J., van Schaik Ron H.N., Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment, 10.1016/j.ejca.2005.08.035
  28. Staatz Christine E., Goodman Lucy K., Tett Susan E., Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I : , 10.2165/11317350-000000000-00000
  29. Staatz Christine E., Goodman Lucy K., Tett Susan E., Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II : , 10.2165/11317550-000000000-00000
  30. Elens Laure, van Schaik Ron H, Panin Nadtha, de Meyer Martine, Wallemacq Pierre, Lison Dominique, Mourad Michel, Haufroid Vincent, Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients, 10.2217/pgs.11.90
  31. Elens Laure, Bouamar Rachida, Hesselink Dennis A., Haufroid Vincent, van Gelder Teun, van Schaik Ron H.N., The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients : , 10.1097/fpc.0b013e328351f3c1
  32. Elens L., Bouamar R., Hesselink D. A., Haufroid V., van der Heiden I. P., van Gelder T., van Schaik R. H. N., A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients, 10.1373/clinchem.2011.165613
  33. Elens Laure, Becker Matthijs L., Haufroid Vincent, Hofman Albert, Visser Loes E., Uitterlinden André G., Stricker Bruno Ch., van Schaik Ron H.N., Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study : , 10.1097/fpc.0b013e32834c6edb
  34. Wang D, Guo Y, Wrighton S A, Cooke G E, Sadee W, Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, 10.1038/tpj.2010.28
  35. Wandel C, CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism, 10.1067/mcp.2000.108506
  36. Tomalik-Scharte D., Doroshyenko O., Kirchheiner J., Jetter A., Lazar A., Klaassen T., Frank D., Wyen C., Fätkenheuer G., Fuhr U., No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam, 10.1007/s00228-008-0503-9
  37. Shih P.-S., Pharmacokinetics of Midazolam and 1'-Hydroxymidazolam in Chinese with Different CYP3A5 Genotypes, 10.1124/dmd.30.12.1491
  38. Miao J, Jin Y, Marunde R L, Kim S, Quinney S, Radovich M, Li L, Hall S D, Association of genotypes of the CYP3A cluster with midazolam disposition in vivo, 10.1038/tpj.2009.21
  39. Lepper E. R., Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients, 10.1158/1078-0432.ccr-05-0520
  40. Kharasch E D, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, Ensign D, Influence of CYP3A5 Genotype on the Pharmacokinetics and Pharmacodynamics of the Cytochrome P4503A Probes Alfentanil and Midazolam, 10.1038/sj.clpt.6100237
  41. HE P, COURT M, GREENBLATT D, VONMOLTKE L, Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo, 10.1016/j.clpt.2004.11.112
  42. Floyd Michael D, Gervasini Guillermo, Masica Andrew L, Mayo Gail, George Alfred L, Bhat Kolari, Kim Richard B, Wilkinson Grant R, Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women : , 10.1097/00008571-200310000-00003
  43. Ball Simon E., Scatina JoAnn, Kao John, Ferron Geraldine M., Fruncillo Richard, Mayer Philip, Weinryb Ira, Guida Marco, Hopkins Penelope J., Warner Natalie, Hall Jeff, Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4, 10.1016/s0009-9236(99)70037-8
  44. Baker S. D., Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients, 10.1158/1078-0432.ccr-04-1371
  45. Ozdemir Vural, Kalow Werner, Tang Bing-Kou, Paterson Andrew, Walker Scott, Endrenyi Laszlo, Kashuba Angela, 10.1097/00008571-200007000-00001
  46. Mathijssen Ron H.J., Loos Walter J., Verweij Jaap, Determining the Best Dose for the Individual Patient, 10.1200/jco.2011.38.2572
  47. CHIOU W, JEONG H, WU T, MA C, Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization, 10.1016/s0009-9236(01)00127-8
  49. Westlind Anna, Löfberg Lena, Tindberg Niclas, Andersson Tommy B., Ingelman-Sundberg Magnus, Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory Region, 10.1006/bbrc.1999.0752
  50. Shimada T., Guengerich F. P., Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver., 10.1073/pnas.86.2.462
  51. Lamba Jatinder K, Lin Yvonne S, Schuetz Erin G, Thummel Kenneth E, Genetic contribution to variable human CYP3A-mediated metabolism, 10.1016/s0169-409x(02)00066-2
  52. P.B. Danielson Bentham Science Publisher, The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans, 10.2174/1389200023337054